SG Americas Securities LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

SG Americas Securities LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 137.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 100,993 shares of the biopharmaceutical company's stock after buying an additional 58,496 shares during the period. SG Americas Securities LLC's holdings in Amicus Therapeutics were worth $824,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock worth $275,619,000 after acquiring an additional 458,143 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock worth $35,866,000 after acquiring an additional 159,139 shares during the period. Northern Trust Corp raised its holdings in Amicus Therapeutics by 5.9% in the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock worth $31,761,000 after purchasing an additional 187,652 shares during the period. Finally, Vestal Point Capital LP purchased a new position in shares of Amicus Therapeutics during the 4th quarter valued at approximately $31,557,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on FOLD shares. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company reduced their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. The Goldman Sachs Group lowered their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Finally, UBS Group raised their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Stock Down 1.6%

Shares of FOLD stock traded down $0.09 on Friday, reaching $5.64. 17,424,827 shares of the stock were exchanged, compared to its average volume of 3,087,315. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -62.66 and a beta of 0.54. The business's 50 day moving average price is $6.40 and its 200 day moving average price is $8.21. The company has a current ratio of 3.34, a quick ratio of 2.47 and a debt-to-equity ratio of 2.02. Amicus Therapeutics, Inc. has a twelve month low of $5.63 and a twelve month high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.